Published on 24 May 2024 on Zacks via Yahoo Finance
Edwards Lifesciences Corporation EW is well poised for growth in coming quarters, backed by the strength of a differentiated portfolio of advanced therapies. The company continues to witness strong performance of its SAPIEN 3 Ultra RESILIA platform, the leading platform in the United States and Japan.
However, stiff rivalry and foreign exchange headwinds are a concern for EW’s business.